12:00 AM
 | 
Nov 04, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ETC-1002: Phase IIb started

Esperion began the double-blind, U.S. Phase IIb ETC-1002-008 trial to evaluate once-daily 120 or 180 mg oral ETC-1002 alone or in combination with 10 mg Zetia ezetimibe for...

Read the full 128 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >